Journal: Stem Cell Research & Therapy

Article Title: rhBMP-2 induces terminal differentiation of human bone marrow mesenchymal stromal cells only by synergizing with other signals

doi: 10.1186/s13287-024-03735-y

Figure Lengend Snippet: Long-term rhBMP-2 treatment of hBM-MSCs does not induce global gene expression rearrangement. The control and rh-BMP-2-treated hBM-MSCs were cultured for 28 days. A , B Scatter plot of gene expression (axes provided on a logarithmic scale) showing selected genes. Lines indicate the limits of differential overexpression or downregulation. The number 57 indicates the genes differentially overexpressed in the rhBMP-2 treatment group. The number 36 indicates the genes downregulated in the rhBMP-2 treatment group. A The key genes involved in the BMP-2 signalling pathway (none of which were differentially expressed). B The main inhibitors of the BMP signalling pathway (noggin (NOG) was the only one differentially overexpressed in the rhBMP-2 treatment group). C Volcano plot of gene expression data showing the overexpression of three rhBMP-2 signalling inhibitor genes related to WNT/β-catenin signalling. D GO terms obtained in the GO analysis of all the differentially expressed genes (Input: log ± 2 genes. n = 93). E Scatter plot of gene expression showing the main osteogenic, adipogenic and chondrogenic differentiation markers. (None of the genes were differentially expressed). Assays were conducted using cells from donor D24. Independent replicate samples (n = 3 per condition) are shown in Additional file : Fig. 1

Article Snippet: Osteogenic differentiation was induced with the Osteogenic Differentiation Medium Bullet Kit (Lonza, Cat.# PT-3002).

Techniques: Expressing, Cell Culture, Over Expression

Journal: Stem Cell Research & Therapy

Article Title: rhBMP-2 induces terminal differentiation of human bone marrow mesenchymal stromal cells only by synergizing with other signals

doi: 10.1186/s13287-024-03735-y

Figure Lengend Snippet: Effect of rhBMP-2 treatment in combination with the osteogenic differentiation media components. Images of cells stained after 28 days of incubation. A Alizarin red staining images of cells incubated in control or complete osteogenic media with or without rhBMP-2. Red staining indicates calcium deposition in the extracellular matrix. B Alizarin red staining images of cells incubated in control media supplemented with ascorbic acid and different concentrations of B-glycerophosphate, with or without rhBMP-2. Red staining indicates calcium deposition in the extracellular matrix. C Alizarin red staining and Oil red O staining images of cells incubated in control media supplemented with dexamethasone and ascorbic acid and with or without rhBMP-2. Oil red O staining indicated adipose droplets. (Dex, dexamethasone; Asc, ascorbic acid; BGP, B-glycerophosphate). n = 3 for each experiment. The data shown correspond to donors D19, D23, D24 and D26

Article Snippet: Osteogenic differentiation was induced with the Osteogenic Differentiation Medium Bullet Kit (Lonza, Cat.# PT-3002).

Techniques: Staining, Incubation

Journal: Stem Cell Research & Therapy

Article Title: rhBMP-2 induces terminal differentiation of human bone marrow mesenchymal stromal cells only by synergizing with other signals

doi: 10.1186/s13287-024-03735-y

Figure Lengend Snippet: Schematic representation of the ability of hBM-MSCs to differentiate in response to rhBMP-2. In vitro, rhBMP-2 treatment induces early osteogenic-chondrogenic marker expression in short-term cultures, while long-term culture fails to induce terminal differentiation features. rhBMP-2 supplementation in osteogenic, adipogenic or chondrogenic differentiation media yields a synergistic effect, potentiating a terminally differentiated phenotype in long-term culture. In vivo, hBM-MSCs implanted in a gelatin carrier scaffold undergo multilineage differentiation due synergy between rhBMP-2 and in vivo bone formation signals

Article Snippet: Osteogenic differentiation was induced with the Osteogenic Differentiation Medium Bullet Kit (Lonza, Cat.# PT-3002).

Techniques: In Vitro, Marker, Expressing, In Vivo